ValuEngine cut shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a strong sell rating in a report issued on Friday morning.
A number of other research firms also recently issued reports on GALT. Zacks Investment Research raised shares of Galectin Therapeutics from a hold rating to a buy rating and set a $2.75 price objective on the stock in a report on Thursday. HC Wainwright raised their price objective on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a buy rating in a report on Tuesday, November 28th. Roth Capital initiated coverage on shares of Galectin Therapeutics in a report on Thursday, October 19th. They issued a buy rating and a $8.00 price objective on the stock. Finally, Seaport Global Securities reissued a buy rating and issued a $5.00 price objective on shares of Galectin Therapeutics in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Galectin Therapeutics presently has a consensus rating of Buy and an average target price of $4.75.
Shares of Galectin Therapeutics (NASDAQ GALT) traded up $0.07 during midday trading on Friday, hitting $2.43. 400,800 shares of the stock were exchanged, compared to its average volume of 358,329. Galectin Therapeutics has a 12-month low of $0.84 and a 12-month high of $3.68.
Several institutional investors and hedge funds have recently bought and sold shares of GALT. Advisor Group Inc. lifted its holdings in Galectin Therapeutics by 7.4% during the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock valued at $1,112,000 after purchasing an additional 35,850 shares in the last quarter. Virtu KCG Holdings LLC lifted its holdings in Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after purchasing an additional 21,008 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after purchasing an additional 134,165 shares in the last quarter. Northern Trust Corp lifted its holdings in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares in the last quarter. Finally, KCG Holdings Inc. lifted its holdings in Galectin Therapeutics by 1.9% during the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock valued at $198,000 after purchasing an additional 1,592 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Galectin Therapeutics (GALT) to Strong Sell” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/04/valuengine-lowers-galectin-therapeutics-galt-to-strong-sell.html.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Galectin Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galectin Therapeutics Inc. and related companies.